Info@ThinkPinkRocks.com

Sanofi, Regeneron reports positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

More here:
Sanofi, Regeneron reports positive Phase 2 study of dupilumab in patients with CSwNP

Share

Leave a Reply

Solve : *
26 − 5 =